Some AML patients with IDH mutations have no response to monotherapy with mIDH inhibitors, and some patients relapsed with elevated circulating levels of 2-HG and acquired resistance to IDH-targeted therapies. The gene discussed is IDH2; the disease is acute myeloid leukemia.